Unknown

Dataset Information

0

Varicella-zoster virus-specific antibody responses in 50-59-year-old recipients of zoster vaccine.

ABSTRACT: Prevaccination and 6-week postvaccination samples from the immunogenicity substudy (n = 2269) of the zoster vaccine (ZV) efficacy trial (N = 22 439) in 50-59-year-old subjects were examined for varicella-zoster virus-specific antibody responses to vaccination. The varicella-zoster virus geometric mean titer (GMT) and geometric mean fold rise were higher in ZV recipients than in placebo recipients (GMT, 660.0 vs 293.1 glycoprotein enzyme-linked immunosorbent assay units/mL [P < .001], respectively; geometric mean fold rise, 2.31 vs 1.00 [P < .025]). In each group there was a strong inverse correlation between postvaccination GMT and risk of subsequent herpes zoster. Although these data provide strong evidence that relates ZV-induced antibody and the risk of herpes zoster, a protective threshold was not determined. Clinical Trials Registration. NCT00534248.

SUBMITTER: Levin MJ 

PROVIDER: S-EPMC4550114 | biostudies-literature | 2013 Nov

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Prevaccination and 6-week postvaccination samples from the immunogenicity substudy (n = 2269) of the zoster vaccine (ZV) efficacy trial (N = 22 439) in 50-59-year-old subjects were examined for varicella-zoster virus-specific antibody responses to vaccination. The varicella-zoster virus geometric mean titer (GMT) and geometric mean fold rise were higher in ZV recipients than in placebo recipients (GMT, 660.0 vs 293.1 glycoprotein enzyme-linked immunosorbent assay units/mL [P < .001], respectivel  ...[more]

Similar Datasets

Unknown Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years.
| S-EPMC4542655 | biostudies-literature
Unknown Clinical Reasoning: A 57-year-old woman with ataxia and oscillopsia: Varicella-zoster encephalitis.
| S-EPMC4999162 | biostudies-literature
Unknown Detection of antibodies to varicella-zoster virus in recipients of the varicella vaccine by using a luciferase immunoprecipitation system assay.
| S-EPMC4178563 | biostudies-literature
Unknown Fatal varicella due to the vaccine-strain varicella-zoster virus.
| S-EPMC4181020 | biostudies-literature
Unknown Herpes zoster caused by vaccine-strain varicella zoster virus in an immunocompetent recipient of zoster vaccine.
| S-EPMC3967828 | biostudies-literature
Unknown Varicella-Zoster Virus-Specific Cellular Immune Responses to the Live Attenuated Zoster Vaccine in Young and Older Adults.
| S-EPMC5505810 | biostudies-literature
Unknown Varicella and herpes zoster vaccine development: lessons learned.
| S-EPMC5942150 | biostudies-literature
Unknown Varicella-Zoster Virus DNA in Blood After Administration of Herpes Zoster Vaccine.
| S-EPMC5939641 | biostudies-literature
Unknown Effectiveness of Live Attenuated Varicella-Zoster Vaccine in Adults Older than 50 Years in Japan: A Retrospective Cohort Study
| S-EPMC9958742 | biostudies-literature
Unknown A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients.
| S-EPMC4327150 | biostudies-literature